Sydney Stoner: Stage IIIB to Stage IV colon cancer with liver and lung involvement

Patient Info: Sydney Stoner, Female, Under 40 | Stage IV

Metastatic Site: Liver; lungs

Progressed from Stage IIIB colon cancer to Stage IV disease involving the liver and lungs; treated with surgery/ileostomy/reversal, FOLFOX/FOLFIRI, lung radiation, liver ablation/resection, capecitabine, and ongoing Lonsurf + Avastin.

Fight Colorectal CancerRead more →

Sexual safety during FOLFOX treatment for Stage III rectal cancer

Patient Info: Anonymized, female, 50s | Stage III

A 54-year-old woman with Stage III rectal cancer raised a practical sexual-health question while receiving FOLFOX, leading to direct measurement of oxaliplatin exposure in vaginal secretions.

PubMed CentralRead more →

Progressive metastatic rectal cancer with bone and brain metastases during palliative pain care

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: bone, brain

By May 2025 the cancer had progressed to bone and brain despite multiple systemic regimens, and anticancer therapy was stopped as care shifted to palliative pain management.

PubMed CentralRead more →

Rectal Cancer Treatment Complicated by a New Bleeding Disorder

Patient Info: Anonymized, female, 60s

The rectal cancer entered complete remission after surgery and 6 cycles of adjuvant chemotherapy.

PubMed CentralRead more →

Stage III Colorectal Cancer: Haley's Survivor Story

Patient Info: Haley Pollack, Female, Under 40 | Stage III

Years into survivorship after Stage IIIC colon cancer treated with surgery, CAPOX chemotherapy, and a recurrence-prevention clinical trial; later continued trial follow-up and advocacy for parents with cancer.

The Patient StoryRead more →

Stage III Colorectal Cancer: Catherine's Patient Story

Patient Info: Catherine, Female | Stage III

Catherine had a complete pathological response after chemoradiation and surgery for Stage III rectal cancer, then continued adjuvant Xeloda/oxaliplatin while waiting for post-treatment scans before accepting an NED label.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Justine's Patient Story

Patient Info: Justine, Female, Under 40 | Stage IV

Metastatic Site: Liver

As of June 2026, Justine was living with Stage IV rectal cancer involving the liver after chemoradiation, major surgery, FOLFOX, and liver-directed local therapies.

The Patient StoryRead more →

Allison’s Stage 2C Colorectal Cancer Story

Patient Info: Allison, Female, Under 40 | Stage II

As of June 2026, Allison was sharing her Stage IIC colorectal cancer experience as a patient advocate after concurrent radiation/Xeloda, major surgery with J-pouch and temporary ileostomy, and chemotherapy.

The Patient StoryRead more →

Stage IV rectal mucinous adenocarcinoma with pancreatic metastasis: response to chemotherapy and staged surgery

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: CA 19-9 93.4 U/mL; CEA 3.4 ng/mL; pancreatic lesion biopsy consistent with colorectal origin

Metastatic Site: pancreas

As of May 2026, he had good clinical progress during 5 months of follow-up after staged treatment, including chemoradiation, FOLFOX, abdominoperineal resection, FOLFIRINOX, and Whipple resection of the pancreatic metastasis.

PubMed CentralRead more →

Rectal cancer that spread through the lungs: complete remission after BRAF-targeted therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: BRAF mutation; HER2-negative; microsatellite stable; no detectable KRAS or NRAS mutations

Metastatic Site: lungs (pulmonary lymphangitic carcinomatosis);…

After progression with recurrent lung metastases and a new pericardial effusion, she chose hospice care and died in February 2025, 19 months after diagnosis.

PubMed CentralRead more →

Stage IV RET-fusion transverse colon cancer: partial response to selpercatinib after capecitabine progression

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Colon cancer had RET fusion, KRAS copy-number gain, low TMB, and no KRAS/NRAS/BRAF hotspot mutations.

Metastatic Site: liver

As of May 2026, she remained on reduced-dose selpercatinib with tolerable toxicity, substantial partial response in liver metastases and the primary tumor, and progression-free survival exceeding 14 months.

PubMed CentralRead more →

Stage IV Colorectal Cancer: Joe's Patient Story

Patient Info: Joe, Male | Stage IV

Biomarkers: Specific biomarkers not reported

Metastatic Site: Liver; lymph nodes; lungs

Stage IV colon cancer initially reached no evidence of disease after FOLFOX plus panitumumab, but later recurred in the liver and lymph nodes, progressed to the lungs, and did not respond to later FOLFOX rechallenge or FOLFIRI before he started an immunotherapy clinical trial.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Sydney's Patient Story

Patient Info: Sydney, Female | Stage IV

Metastatic Site: Liver; lungs

Sydney was living with Stage IV colorectal cancer involving the liver and lungs. After multiple lines of treatment, she had a new liver spot and was back on lower-dose FOLFIRI every other Tuesday with a 46-hour pump.

The Patient StoryRead more →

Stage IV KRAS-mutant colorectal cancer with bilobar liver metastases: multimodality treatment and no evidence of disease

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: KRAS-mutated; BRAF wild-type; mismatch repair proficient

Metastatic Site: liver

After second liver resection, follow-up MRI at 8 weeks showed continued response at the SABR site and no recurrent disease; she was receiving adjuvant capecitabine and remained well.

PubMed CentralRead more →

The Cancer Spread One Year Later…

Patient Info: Kalei, Female, Under 40 | Stage IV

Metastatic Site: Lungs; bilateral lung nodules

Kalei initially had Stage II rectal cancer that responded to chemoradiation and IV chemotherapy without rectal surgery. In 2025, biopsy-proven lung metastasis changed the diagnosis to Stage IV. As of October 2025, she had undergone lung resections with clear margins and remained in ongoing follow-up rather than having a clearly stated NED status.

The Patient StoryRead more →

Kidney complication after switching colorectal cancer chemotherapy regimens

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver

The cancer had worsening liver metastases when FTD/TPI began. After treatment was stopped, steroid therapy resolved edema within 1 month and proteinuria returned to baseline 2.5 months after admission; the later cancer course was not established.

PubMed CentralRead more →

Stage IV transverse colon cancer with NTRK fusion: entrectinib response followed by fatal PTTM

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: RAS/BRAF wild type, low TMB. CEA and CA19-9 were elevated before entrectinib and fell with response.

Metastatic Site: peritoneum, greater omentum, pleura,…

He died 7 weeks after hospitalization from pulmonary tumor thrombotic microangiopathy causing severe pulmonary hypertension and right-heart failure, despite biochemical and ascites response to entrectinib.

PubMed CentralRead more →

MSI-H locally advanced right colon cancer: pathologic complete response after oxaliplatin, capecitabine, and immunotherapy

Patient Info: Anonymized, Female, 60s

Biomarkers: MSI-H on tumor gene testing

After oxaliplatin, capecitabine, and sindilizumab conversion therapy followed by laparoscopic radical right hemicolectomy, postoperative pathology showed no viable tumor cells and tumor regression grade 0 complete response.

PubMed CentralRead more →

Metastatic rectal cancer responding well after intensive treatment despite severe chemotherapy complications

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: KRAS exon 4 mutation, BRAF wild-type, PD-L1 CPS 2

Metastatic Site: liver, lung

After more than 14 months of treatment, the primary rectal tumor and most lung metastases had been resected, liver lesions had largely regressed, and he was described as near NED while continuing maintenance capecitabine plus bevacizumab.

PubMed CentralRead more →

NRG1-Fusion Colorectal Cancer Progressing on Afatinib

Patient Info: Anonymized, female, 70+

Biomarkers: CD74-NRG1 fusion; no KRAS alteration detected

The cancer progressed clinically after 8 weeks on afatinib. She died in November 2021.

PubMed CentralRead more →

Stage II Colorectal Cancer: Tracy's Survivor Story

Patient Info: Tracy, Female, 40s | Stage II

As of February 2025, Tracy was in post-treatment survivorship after Stage IIB colorectal cancer treated with 28 days of Xeloda chemoradiation, colostomy surgery in December 2015, and discontinued post-surgery chemotherapy.

The Patient StoryRead more →

Stage IV cecum cancer with liver and ovarian metastases: ramucirumab-related nephrotic syndrome and glomerular microangiopathy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Cancer biomarkers were not reported. Kidney injury workup showed severe protein leakage and biopsy-proven glomerular microangiopathy.

Metastatic Site: liver, right ovary

The liver metastasis shrank after XELOX plus bevacizumab and metastatic liver/ovarian sites were resected, but ramucirumab-based second-line therapy was stopped after nephrotic syndrome and severe glomerular microangiopathy; blood pressure and proteinuria improved with telmisartan.

PubMed CentralRead more →

Stage III Colorectal Cancer: Jose's Survivor Story

Patient Info: Jose Santos, Male, 40s | Stage III

As of December 2024, more than 2 years after surgery for Stage III colorectal cancer, Jose had no evidence of disease, had adapted well to his ileostomy, and no longer had ulcerative colitis symptoms.

City of HopeRead more →

Stage III Colorectal Cancer: Paul's Patient Story

Patient Info: Paul Klug, Male | Stage III

As of October 2024, Paul was on the final day of round 4 of 5 planned chemotherapy rounds, with chemoradiation and possible resection surgery still ahead.

The Patient StoryRead more →